Hospital-acquired pneumonia (HAP) questions are “Q-bank classics” because they force you to do two things at once: (1) recognize where the pneumonia was acquired and (2) pick empiric therapy that matches the likely organisms and the patient’s risk factors for resistance. The trick is that the wrong answers are often reasonable—just for a different setting, timeline, or pathogen. Let’s break one down the way the test writers think.
Clinical Vignette (Q-bank style)
A 67-year-old man is evaluated for fever and worsening shortness of breath. He was admitted 5 days ago for an ischemic stroke complicated by dysphagia. He has been receiving tube feeds and has required frequent suctioning. Over the last 24 hours, he developed a cough with purulent sputum and pleuritic chest pain. Temperature is 38.9°C (102°F), BP 128/76 mm Hg, HR 112/min, RR 26/min, and oxygen saturation is 90% on 4 L/min nasal cannula. Lung exam reveals crackles over the right lower lobe. WBC count is 17,800/µL. Chest x-ray shows a new right lower lobe infiltrate.
Which of the following is the best empiric antibiotic regimen?
A. Azithromycin + ceftriaxone
B. Piperacillin-tazobactam + vancomycin
C. Amoxicillin-clavulanate
D. Cefepime + doxycycline
E. Clindamycin
Step 1: Identify the Syndrome and Setting
This is hospital-acquired pneumonia (HAP) because:
- Pneumonia onset is ≥ 48 hours after admission (here: day 5)
- There’s a new infiltrate + systemic infection signs (fever, leukocytosis) + respiratory symptoms (cough, hypoxemia)
Also note key risk features:
- Stroke + dysphagia + tube feeds + suctioning → aspiration risk (but in the hospital)
- Hospital setting shifts likely pathogens toward nosocomial gram-negatives and MRSA, not just oral anaerobes
Correct Answer: B. Piperacillin-tazobactam + vancomycin
Why this is right
Empiric treatment of HAP generally needs coverage for:
- MRSA (especially if risk factors present or local MRSA prevalence is high)
- Pseudomonas and other gram-negative rods
Piperacillin-tazobactam covers:
- Pseudomonas
- Many other gram-negative rods (including Enterobacterales)
- Anaerobes (useful if aspiration is in play)
Vancomycin covers:
- MRSA (also linezolid is an alternative)
High-yield organisms in HAP/VAP
Think: “ICU bugs”
- Pseudomonas aeruginosa
- MRSA
- Klebsiella, E. coli, Enterobacter (and other gram-negative rods)
- Acinetobacter
Board pearl: Aspiration in the hospital doesn’t automatically mean “anaerobes → clindamycin.” In HAP/VAP, the pathogen pool is dominated by gram-negative rods and MRSA, and empiric therapy needs to reflect that.
Why Every Other Answer Choice Is Wrong (and when it would be right)
A. Azithromycin + ceftriaxone
Why it’s wrong here: This is classic community-acquired pneumonia (CAP) coverage. It targets:
- “Typical” CAP organisms (S. pneumoniae, H. influenzae)
- “Atypicals” with azithro (Mycoplasma, Chlamydophila, Legionella)
But it misses Pseudomonas and usually misses MRSA, which are major concerns in HAP.
When it’s right: Non-severe inpatient CAP (no MRSA/Pseudomonas risk factors).
High-yield clue for CAP vs HAP:
- CAP: symptoms start outside hospital or within first 48 hours of admission
- HAP: symptoms start after 48 hours in hospital
C. Amoxicillin-clavulanate
Why it’s wrong here: Too narrow for HAP. It doesn’t reliably cover:
- Pseudomonas
- MRSA
When it’s right: Outpatient infections like:
- Mild CAP in some settings (depending on guidelines/risk factors)
- Sinusitis/otitis
- Human/animal bites (Pasteurella + anaerobes)
Test-writer trap: “Aspiration risk” makes students jump to anaerobe coverage. But the setting (HAP) should override the impulse to treat like community aspiration pneumonia.
D. Cefepime + doxycycline
Why it’s wrong here: Cefepime is anti-pseudomonal (good), but this combo is missing reliable MRSA coverage.
- Cefepime: good for Pseudomonas and many gram-negatives, but not anaerobes, and not MRSA
- Doxycycline: can cover atypicals and some community pathogens; not appropriate MRSA coverage for HAP empiric therapy
When it’s right: This pairing is more of a “mismatched” regimen; you might see:
- Cefepime + vancomycin (or linezolid) used for HAP/VAP
- Doxycycline used in CAP regimens (especially outpatient) for atypicals
High-yield: For HAP, atypical coverage is not the priority the way it is in CAP.
E. Clindamycin
Why it’s wrong here: Clindamycin is the classic “aspiration” distractor because it covers:
- Anaerobes
- Gram-positive cocci (but not MRSA reliably in this context)
But it does not cover Pseudomonas and is inadequate for HAP empiric therapy.
When it’s right (boards):
- Some cases of aspiration pneumonia acquired in the community (historically tested)
- Lung abscess with anaerobes (often foul-smelling sputum, poor dentition)
- Certain skin/soft tissue infections (CA-MRSA in select cases, depending on local resistance)
Modern nuance you should know for Step questions: Anaerobes are more classically associated with lung abscess or necrotizing infection rather than routine aspiration pneumonitis/pneumonia—especially in hospitalized patients where gram-negatives and S. aureus dominate.
Mini-Algorithm: How to Approach HAP/VAP on USMLE
1) Confirm timing and setting
- HAP: ≥ 48 hours after admission
- VAP: ≥ 48 hours after intubation (a subset of HAP)
2) Decide what you must cover empirically
Most Step-style empiric coverage includes:
- Anti-pseudomonal beta-lactam
- piperacillin-tazobactam, cefepime, meropenem/imipenem, levofloxacin (less commonly as sole agent)
- MRSA agent
- vancomycin or linezolid
Some real-world protocols add dual anti-pseudomonal coverage in high-resistance settings; on USMLE, the key concept is Pseudomonas + MRSA coverage when HAP/VAP is suspected.
3) De-escalate once cultures return
- Sputum culture and blood cultures help narrow therapy
- De-escalation is a stewardship favorite and shows up in explanations
High-Yield Differentials That Masquerade as “HAP”
Use these to sanity-check the stem:
| Condition | Key clues | Why it matters |
|---|---|---|
| Aspiration pneumonitis (chemical) | Acute after witnessed aspiration, rapid hypoxemia; may have fever but often improves within 24–48h | Often supportive care, antibiotics not always needed unless infection develops |
| Pulmonary embolism | Pleuritic chest pain, tachycardia, hypoxemia; infiltrate may be absent or wedge-shaped | Antibiotics won’t fix it; look for risk factors and D-dimer/CTPA logic |
| CHF/pulmonary edema | Bilateral crackles, S3, cardiomegaly, Kerley B lines | Treat with diuresis, not antibiotics |
| CAP | Symptoms begin before admission or within 48h | Different bug set → different empiric regimen |
Take-Home Points (what the exam wants you to say)
- HAP = pneumonia ≥ 48 hours after admission → think MRSA + Pseudomonas until proven otherwise.
- Aspiration risk in a hospitalized patient does not narrow you to anaerobes; it broadens concern to nosocomial flora.
- CAP regimens (ceftriaxone + azithro, doxycycline-based plans) are common distractors and are not adequate for HAP.
- Clindamycin is the “anaerobe” trap: good for lung abscess/community aspiration, but not for HAP.